Research ArticleArticle
Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various In Vitro Experimental Systems: Implications for Universal Digoxin DDI Risk Assessment Decision Criteria
Joe E Bentz, Mike O'Connor, Dallas Bednarczyk, Joann Coleman, Caroline A. Lee, Johan E Palm, Anne Pak, Elke S Perloff, Eric L Reyner, Praveen Balimane, Marie Brannstrom, Xiaoyan Chu, Christoph Funk, Ailan Guo, Imad H Hanna, Krisztina Heredi-Szabo, Kathleen M Hillgren, Libin Li, Evelyn Hollnack-Pusch, Masoud Jamei, Xuena Lin, Andrew Mason, Sibylle Neuhoff, Aarti Patel, Lalitha Podila, Emile Plise, Ganesh Rajaraman, Laurent Salphati, Eric Sands, Mitchell E Taub, Jesse Taur, Dietmar Weitz, Heleen Wortelboer, Cindy Xia, Guangqing Xiao, Jocelyn Yabut, Tetsuo Yamagata, Lei K Zhang and Harma Ellens
Drug Metabolism and Disposition April 25, 2013, dmd.112.050500; DOI: https://doi.org/10.1124/dmd.112.050500
Joe E Bentz
1 Drexel University;
Mike O'Connor
1 Drexel University;
Dallas Bednarczyk
2 Optivia Biotechnology;
Joann Coleman
3 GlaxoSmithKline Pharmaceuticals;
Caroline A. Lee
4 DMPK Solutions, Inc;
Johan E Palm
5 AstraZeneca R&D Molndal;
Anne Pak
6 Eli Lilly and Company;
Elke S Perloff
7 BD Biosciences Discovery Labware, BD Gentest Contract Research Services;
Eric L Reyner
8 Pfizer;
Praveen Balimane
9 Bristol-Myers Squibb;
Marie Brannstrom
10 Astrazeneca;
Xiaoyan Chu
11 Merck & Co.,;
Christoph Funk
12 F. Hoffmann-La Roche Ltd.;
Ailan Guo
13 Hoffman-La Roche;
Imad H Hanna
14 Novartis Institutes for BioMedical Research;
Krisztina Heredi-Szabo
15 Solvo Biotechnology;
Kathleen M Hillgren
16 Lilly Research Laboratories;
Libin Li
17 Absorption Systems;
Evelyn Hollnack-Pusch
18 F. Hoffmann-La Roche;
Masoud Jamei
19 Simcyp Ltd;
Xuena Lin
20 Novartis Institute for Biomedical Research;
Andrew Mason
21 BD Biosciences Discovery Labware, BD Gentest Contract Reserach Services;
Sibylle Neuhoff
19 Simcyp Ltd;
Aarti Patel
3 GlaxoSmithKline Pharmaceuticals;
Lalitha Podila
22 Boehringer Ingelheim Parmaceuticals;
Emile Plise
23 Genentech Inc;
Ganesh Rajaraman
24 CellzDirect-Life Technologies;
Laurent Salphati
25 Genentech;
Eric Sands
26 Biogen Idec;
Mitchell E Taub
27 Boehringer Ingelheim Pharmaceuticals, Inc.;
Jesse Taur
28 Eisai;
Dietmar Weitz
29 Sanofi-Aventis;
Heleen Wortelboer
30 TNO;
Cindy Xia
31 Millennium Pharmaceutics, Inc.;
Guangqing Xiao
26 Biogen Idec;
Jocelyn Yabut
32 Merck & Co.;
Tetsuo Yamagata
33 Merck Serono;
Lei K Zhang
34 Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Re
Harma Ellens
3 GlaxoSmithKline Pharmaceuticals;
Supplemental Data
Files in this Data Supplement:
- Supplemental Data -
IC50 values